| Literature DB >> 16884309 |
Syaulan Yang1, Shu-Jen Chen, Min-Feng Hsu, Jen-Dar Wu, Chien-Te K Tseng, Yu-Fan Liu, Hua-Chien Chen, Chun-Wei Kuo, Chi-Shen Wu, Li-Wen Chang, Wen-Chang Chen, Shao-Ying Liao, Teng-Yuan Chang, Hsin-Hui Hung, Hui-Lin Shr, Cheng-Yuan Liu, Yu-An Huang, Ling-Yin Chang, Jen-Chi Hsu, Clarence J Peters, Andrew H-J Wang, Ming-Chu Hsu.
Abstract
A potent SARS coronavirus (CoV) 3CL protease inhibitor (TG-0205221, Ki = 53 nM) has been developed. TG-0205221 showed remarkable activity against SARS CoV and human coronavirus (HCoV) 229E replications by reducing the viral titer by 4.7 log (at 5 microM) for SARS CoV and 5.2 log (at 1.25 microM) for HCoV 229E. The crystal structure of TG-0205221 (resolution = 1.93 A) has revealed a unique binding mode comprising a covalent bond, hydrogen bonds, and numerous hydrophobic interactions. Structural comparisons between TG-0205221 and a natural peptide substrate were also discussed. This information may be applied toward the design of other 3CL protease inhibitors.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16884309 DOI： 10.1021/jm0603926
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446